BIOPHARM-APPL T BIO 润色咨询

biopharm-the applied technologies of biopharmaceutical development

出版年份：暂无数据 年文章数：0 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1088011, encodeId=0a3910880115e, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088012, encodeId=ce3910880128b, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520943, encodeId=f0b252094352, content=审稿速度:1.0<br>经验分享：PHARM DEV TECHNOL 投稿1天后悲剧（被拒） <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:50:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    撰写摘要有什么要点？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1088011, encodeId=0a3910880115e, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088012, encodeId=ce3910880128b, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520943, encodeId=f0b252094352, content=审稿速度:1.0<br>经验分享：PHARM DEV TECHNOL 投稿1天后悲剧（被拒） <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:50:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2021-12-28 MS68862005

    摘要需要详细到什么程度？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1088011, encodeId=0a3910880115e, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088012, encodeId=ce3910880128b, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520943, encodeId=f0b252094352, content=审稿速度:1.0<br>经验分享：PHARM DEV TECHNOL 投稿1天后悲剧（被拒） <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=228, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:50:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2016-04-01 witcui

    审稿速度:1.0
    经验分享：PHARM DEV TECHNOL 投稿1天后悲剧（被拒）

    0

共5条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分